X hits on this document

514 views

0 shares

0 downloads

0 comments

31 / 147

96.

While

the

confidential

information

and

documentation

that

would

reveal

additional names, dates, times, and places relating to the negotiation and implementation of the

illegal Market Share Agreement is solely within the possession of Bristol Myers and Omnicare,

Lisitza's superiors conceded the existence, implementation, and financial impact of the Monopril

Market Share Agreement to Lisitza and instructed him about what he was required to do to

accomplish the financial objective ofthe Monopril Market Share Agreement.

97.

Accordingly,

before

his

termination,

Lisitza

personally

filled

hundreds

of

"switched"

prescriptions

for

Monopril

while

employed

by

Omnicare.

He

also

witnessed

thousands of prescriptions switched pursuant to the Monopril Market Share Agreement.

98.

Bristol Myers worked with other large entities who dispensed pharmaceuticals,

including dispensing pharmacies, pharmacy benefit managers, and hospitals, to illegally gain

market share for Monopril in the ACE inhibitor market through illegal kickbacks-for-switches

schemes similar to the one effected with Omnicare. The specific circumstances alleged herein

evidence a pattern of conduct by Bristol Myers designed to maximize profits through this scheme

at every 0ppOliunity, through various other drugs and other providers.

  • E.

    AFTER THE SUCCESS OF THE BRISTOL MVERSIMONOPRIL PAL PROGRAM, OTHER DEFENDANT MANUFACTURERS ENTER INTO SIMILAR SCHEMES WITH OMNICARE WITH SIMILAR RESULTS AND RISKS

    • 99.

      The mechanics of the Bristol Myers/Omnicare scheme set the framework for

subsequent schemes entered into by the other Defendant Manufacturers and Omnicare. In each

case, a drug within a commonly prescribed therapeutic class - antibiotics for bedsores and other

infections, blood pressure and cholesterol medications, antipsychotics for dementia - became a

"preferred" medication because a Defendant Manufacturer paid bribes to make it so,

notwithstanding the cost to the government or the impact on the patient's health.

27

Document info
Document views514
Page views514
Page last viewedTue Dec 06 14:49:05 UTC 2016
Pages147
Paragraphs7751
Words41508

Comments